Perspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham Acquires 33,333 Shares

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham purchased 33,333 shares of the business’s stock in a transaction dated Friday, March 28th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the acquisition, the chief financial officer now owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Perspective Therapeutics Stock Down 8.0 %

Perspective Therapeutics stock traded down $0.17 during trading hours on Tuesday, hitting $1.96. The company had a trading volume of 891,750 shares, compared to its average volume of 999,366. Perspective Therapeutics, Inc. has a one year low of $1.91 and a one year high of $19.05. The firm has a 50-day moving average of $2.91 and a 200 day moving average of $6.19.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Perspective Therapeutics by 19.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock worth $224,000 after buying an additional 11,472 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in Perspective Therapeutics in the 4th quarter worth about $1,595,000. Squarepoint Ops LLC bought a new stake in Perspective Therapeutics in the 4th quarter valued at about $626,000. Wexford Capital LP acquired a new position in shares of Perspective Therapeutics during the 4th quarter worth approximately $64,000. Finally, Two Sigma Advisers LP bought a new position in shares of Perspective Therapeutics during the fourth quarter worth approximately $484,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CATX. Scotiabank began coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Monday. Royal Bank of Canada cut their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $14.44.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.